Russell Investments Group
BCAX

Russell Investments Group’s Bicara Therapeutics BCAX Stock Holding History

Russell Investments Group’s Portfolio BCAX Stock Details BCAX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$990K Buy
33,339
+13,446
+68% +$300K ﹤0.01% 2468
2026
Q1 		$396K Sell
19,893
-36,705
-65% -$632K ﹤0.01% 2593
2025
Q4 		$953K Buy
56,598
+17,472
+45% +$298K ﹤0.01% 2237
2025
Q3 		$618K Buy
39,126
+11,654
+42% +$130K ﹤0.01% 2390
2025
Q2 		$255K Buy
+27,472
New +$327K ﹤0.01% 2577

Other funds holding BCAX

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
RTM
Red Tree Management Redwood City, California $147M AUM 202.18% 1-Year Est. Return
TGA
TPG GP A Fort Worth, Texas $5B AUM 58.56% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Russell Investments Group's BCAX Position: Q2 2026 in Review

Russell Investments Group increased its Bicara Therapeutics (BCAX) stake by 68% in Q2 2026, buying an estimated $300K and bringing the position to 33,339 shares worth $990K. The position accounts for ﹤0.01% of the portfolio, ranked #2468.

Russell Investments Group first reported a position in BCAX in Q2 2025 and has held it in 5 quarters since. 172 funds tracked by Wall St. Rank hold BCAX as of Q2 2026.

  • Russell Investments Group held 33,339 shares of Bicara Therapeutics worth $990K as of Q2 2026.
  • Russell Investments Group bought 13,446 Bicara Therapeutics shares in Q2 2026, an estimated $300K.
  • Bicara Therapeutics made up ﹤0.01% of Russell Investments Group's portfolio in Q2 2026, its #2468 holding.
  • Russell Investments Group first reported a position in Bicara Therapeutics in Q2 2025 and has held it in 5 quarters since.
  • 172 funds tracked by Wall St. Rank held Bicara Therapeutics as of Q2 2026.

Based on Russell Investments Group's 13F filing for Q2 2026, filed 6 Aug 2026.